Sanofi Chief Digital Officer Emmanuel Frenehard on scaling AI across a Big Pharma global enterprise and why a strategy of ...
A joint framework is being built to convert Israeli academic target biology into viable small-molecule programs by integrating AI-enabled design with rigorous experimental validation. ChemPass AI™ ...
Modern biopharma firms are adapting their R&D investment strategies in response to challenges such as the impending $300 ...
Bansi Nagji, CEO of PANTHERx Rare, explores how innovation is increasingly directed toward rare and orphan diseases, driven ...
In today's Pharmaceutical Executive Daily, Vertex Pharmaceuticals announces a $10 billion acquisition of Crinetics ...
Jay Bregman, CEO and co-founder of Andel, discusses how FDA’s action signals a broader regulatory recalibration aimed at protecting intellectual property and explores the second-order effects. Jay ...
Transaction terms include $85-per-share all-cash consideration (~$10B enterprise value) and an anticipated Q3 2026 close, contingent on customary conditions. Portfolio fit emphasizes serious, ...
Novartis is buying Myricx to internalize an NMTi-based ADC payload platform intended to expand ADC applicability and ...
Zymeworks will pay $17.00/share (~$929M) for Theravance, prioritizing Yupelri-linked profitability and planned post-close ...
It was a jarring experience that stemmed from a startlingly common misconception: that adults don't get T1D; however, she is ...
Resilient field models emphasize continuous territory coverage via agile deployment, blending scalable virtual reach with ...
For pharmaceutical executives, the transition from just extending to fully optimizing life is a defining commercial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results